Shares of ACADIA Pharmaceuticals (ACAD 0.61%) shot through the roof today, up 30% as of this filming. In the video below, Fool health-care analyst David Williamson discusses news of some great phase 3 trial results for the company's drug Pimavanserin, which treats psychosis in patients with Parkinson's disease. David tells investors how good the results were, and what advantages this drug candidate could have over its competition if it reaches FDA approval.
What Acadia Investors Need to Know About This Stock's Pop Today
By Dave Williamson – Mar 21, 2013 at 5:12PM
NASDAQ: ACAD
Acadia Pharmaceuticals
Market Cap
$3.6B
Today's Change
(-0.61%) $0.13
Current Price
$21.26
Price as of October 23, 2025 at 10:52 AM ET
Acadia shares jumped today. Here are the key reasons why that you need to know.
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid